Drugs / GQ1010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06464055 | May 2024 → May 2028 expected | cancer | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GQ1010 | “This is a Phase 1/2, first in human (FIH), open-label, multicenter study of GQ1010, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated,...” NCT06464055 ↗ |
| Modality | Other / unclassified | “a Trop-2 directed antibody-drug conjugate (ADC)” NCT06464055 ↗ |
| Route | Intravenous | “GQ1010 will be administered intravenously every 21 days or every 14 days.” NCT06464055 ↗ |